Remove 2021 Remove Clinical Development Remove Licensing
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Carlos specialises in helping pharmaceutical and biotechnology companies develop their in- and out-licensing strategies, with additional expertise and experience in portfolio assessment and prioritisation, drug candidate valuation, valuation and related services. Using clinical genomics and AI in drug development to elevate success.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why smarter financial planning could be key to clinical trial success

Drug Target Review

This approach also helps maintain visibility, accuracy and financial control, which are critical for navigating the uncertainties that arise throughout clinical development. Kyle previously consulted for biotech finance teams at JDK Consulting & Advisory (2018–2021), following senior finance roles at Gerrity Group and PIRCH.

article thumbnail

Optimizing Your Drug Patent Strategy: A Comprehensive Guide for Pharmaceutical Companies

Drug Patent Watch

Licensing and Partnerships A strong patent portfolio can open doors to lucrative licensing agreements and strategic partnerships. According to a report by the Biotechnology Innovation Organization, licensing deals in the pharmaceutical industry averaged $450 million in 2020[1].

article thumbnail

EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen

The Pharma Data

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. ,

article thumbnail

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

The Pharma Data

COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China. Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged.

article thumbnail

AstraZeneca takes COVID-19 vaccine to China with BioKangtai deal for 200M-dose capacity by 2021

The Pharma Data

AstraZeneca reached a licensing deal with Chinese firm BioKangtai to help provide its adenovirus vector-based COVID-19 vaccine candidate, created by the University of Oxford, to China, AstraZeneca said (Chinese) in a social media post on Thursday. China has several home-grown COVID-19 vaccines in clinical development.